Company intelligence / Profile preview
George Medicines
Staines-Upon-Thames, England, United Kingdomgeorge-medicines.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
George Medicines develops late-stage, single-pill combination therapies to address significant unmet needs in cardiometabolic diseases. Their approach leverages existing best-in-class treatments combined into innovative formulations. Lead programs are in advanced clinical trials targeting hypertension and cardiovascular risk reduction. Recent licensing agreements indicate progress toward commercialization.
- Therapeutic areas
- CardiovascularMetabolic Disorders
- Modalities
- Small moleculesfixed-dose combination therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Medisanté (IoT data collection collaboration)Bausch Health (exclusive licensing agreement for certain territories)Contractual pharmaceutical/clinical development partners
Beyond the preview
Go deeper on George Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on George Medicines.